Bionano Genomics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and (Unaudited)
Condensed Consolidated Balance Sheets
| (Unaudited) | ||
|---|---|---|
| September 30,2025 | December 31,2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,065,000 | $9,173,000 |
| Investments | 18,516,000 | 302,000 |
| Accounts receivable, net | 4,526,000 | 4,752,000 |
| Inventory | 7,049,000 | 11,121,000 |
| Prepaid expenses and other current assets | 5,378,000 | 3,141,000 |
| Restricted investments | 10,266,000 | 11,000,000 |
| Total current assets | 48,800,000 | 39,489,000 |
| Restricted cash | — | 400,000 |
| Property and equipment, net | 16,172,000 | 19,219,000 |
| Operating lease right-of-use assets | 3,497,000 | 1,804,000 |
| Finance lease right-of-use assets | 3,146,000 | 3,299,000 |
| Intangible assets, net | 5,685,000 | 9,705,000 |
| Other long-term assets | 1,762,000 | 2,754,000 |
| Total assets | $79,062,000 | $76,670,000 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | 5,990,000 | 6,962,000 |
| Accrued expenses | 4,706,000 | 5,641,000 |
| Contract liabilities | 1,180,000 | 1,128,000 |
| Operating lease liability | 1,025,000 | 2,991,000 |
| Finance lease liability | 251,000 | 260,000 |
| Convertible debentures payable (at fair value) | 9,825,000 | 20,362,000 |
| Total current liabilities | 22,977,000 | 37,344,000 |
| Operating lease liability, net of current portion | 2,599,000 | 145,000 |
| Finance lease liability, net of current portion | 3,495,000 | 3,539,000 |
| Long-term contract liabilities | 192,000 | 267,000 |
| Total liabilities | $29,263,000 | $41,295,000 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value, 400,000,000 shares authorized at September 30, 2025 and December 31, 2024; 9,730,400 and 1,865,400 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 1,000 | — |
| Additional paid-in capital | 761,479,000 | 728,573,000 |
| Accumulated deficit | (711,687,000) | (693,225,000) |
| Accumulated other comprehensive income | 6,000 | 27,000 |
| Total stockholders’ equity | $49,799,000 | $35,375,000 |
| Total liabilities and stockholders’ equity | $79,062,000 | $76,670,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.